Revenue growth of 99% YoY with accelerating consumable pull-through signals strong product-market fit for NULISA platform. The $197.8M IPO cash eliminates near-term funding risk. Watch for full-year guidance in August — if revenue trajectory sustains, the stock could re-rate higher. The $8.6M convertible note loss is non-cash and one-time.
Price Chart
Executive Summary
Alamar Biosciences reported Q1 2026 revenue of $26.0M, a 99% YoY increase, driven by 178% consumable revenue growth. Net loss widened to $21.3M from $7.7M due to a $8.6M convertible note remeasurement loss. The company completed a $197.8M net IPO in April 2026 and will provide full-year 2026 guidance in August.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue $26.0M, up 99% YoY from $13.1M
- Consumable revenue grew 178% YoY to $14.0M
- Gross margin expanded to 56% from 49% YoY
- Net loss $21.3M vs $7.7M YoY, includes $8.6M convertible note remeasurement loss
- Completed IPO in April 2026, raising $197.8M net proceeds
- Full-year 2026 revenue guidance to be provided in August 2026
Financial Impact
Revenue nearly doubled YoY to $26.0M; gross margin improved 700 bps to 56%; IPO added $197.8M net cash to balance sheet
Risk Factors
- Operating expenses grew 79% YoY, outpacing revenue growth rate
- No full-year guidance provided yet — uncertainty on H2 trajectory
- Net loss widened significantly due to convertible note remeasurement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-213379 |
| Document: ck0002104204-20260508.htm | 0001193125-26-213379 |
| Document: 0001193125-26-213379-index-headers.html | 0001193125-26-213379 |
| Document: 0001193125-26-213379-index.html | 0001193125-26-213379 |
| Document: 0001193125-26-213379.txt | 0001193125-26-213379 |
| 8-K Data (Synthetic) | 0001193125-26-213379 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | 144 | $27.42 | awaiting T+60 | — | $30.71 (−12.00%) |
Oct 14, 2026 11d ago | 144 | $27.42 | awaiting T+60 | — | $30.71 (−12.00%) |
Oct 14, 2026 11d ago | 144 | $27.42 | awaiting T+60 | — | $30.71 (+12.00%) |
Oct 5, 2026 20d ago | Press Release | $32.26 | awaiting T+60 | — | $30.71 (−4.80%) |
Sep 24, 2026 4w ago | Press Release | $32.80 | awaiting T+60 | — | $30.71 (−6.37%) |
Sep 1, 2026 7w ago | 8-K | $30.49 | awaiting T+60 | — | $30.71 (+0.72%) |
Aug 10, 2026 10w ago | 8-K | $36.57 | awaiting T+60 | — | $30.71 (−16.02%) |
Jul 13, 2026 15w ago | Press Release | $27.40 $32.26 | ▲ +17.74% | ▲ +13.74% | $30.71 (+12.08%) |
Jul 10, 2026 15w ago | Press Release | $28.42 $38.13 | ▲ +34.17% | ▲ +31.53% | $30.71 (+8.06%) |
May 8, 2026 24w ago | 8-K | $23.96 $27.11 | ▲ +13.15% | ▲ +8.31% | $30.71 (+28.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers